Pyruvate therapy for Leigh syndrome due to cytochrome c oxidase deficiency

Biochimica et Biophysica Acta - General Subjects

Volumn 1800, Issue 3, 2010, Pages 313-315

  Komaki, Hirofumi ^a,b   Nishigaki, Yutaka ^c   Fuku, Noriyuki ^c   Hosoya, Hiroko ^c   Murayama, Kei ^d   Ohtake, Akira ^e   Goto, Yu ichi ^a,b   Wakamoto, Hiroyuki ^f   Koga, Yasutoshi ^g   Tanaka, Masashi ^c  

^a National Center Hospital of Neurology and Psychiatry   (Japan)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^c TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^d CHIBA CHILDREN'S HOSPITAL   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f Ehime Rehabilitation Center for Children   (Japan)

^g KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytochrome c oxidase deficiency; Exercise intolerance; Lactate to pyruvate ratio; Leigh syndrome; Pyruvate therapy

Indexed keywords

CYTOCHROME C OXIDASE; LACTIC ACID; PYRUVATE SODIUM; UBIQUINONE; MITOCHONDRIAL DNA; PYRUVIC ACID;

ARTICLE; CARDIOMYOPATHY; CASE REPORT; CHILD; CYTOCHROME C OXIDASE DEFICIENCY; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FEMALE; GASTROINTESTINAL INFECTION; HEART CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LACTATE BLOOD LEVEL; LEIGH DISEASE; MAINTENANCE DRUG DOSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RUNNING; SCHOOL CHILD; T WAVE INVERSION; ABDUCENS NERVE PARALYSIS; BRAIN DAMAGE; CEREBROSPINAL FLUID LEVEL; CONFERENCE PAPER; GENE MUTATION; MOTOR DYSFUNCTION; NYSTAGMUS;

ADULT; CYTOCHROME-C OXIDASE DEFICIENCY; DNA; DNA, MITOCHONDRIAL; ELECTRON TRANSPORT COMPLEX IV; FEMALE; HUMANS; LEIGH DISEASE; MAGNETIC RESONANCE IMAGING; MUTATION; NYSTAGMUS, PATHOLOGIC; PYRUVATES;

EID: 77049093212     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2009.07.008     Document Type: Article

References (14)

1. Tanaka M., Borgeld H.J., Zhang J., Muramatsu S., Gong J.S., Yoneda M., Maruyama W., Naoi M., Ibi T., Sahashi K., Shamoto M., Fuku N., Kurata M., Yamada Y., Nishizawa K., Akao Y., Ohishi N., Miyabayashi S., Umemoto H., Muramatsu T., Furukawa K., Kikuchi A., Nakano I., Ozawa K., and Yagi K. Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria. J. Biomed. Sci. 9 (2002) 534-541
2. Naito E., Ito M., Yokota I., Saijo T., Ogawa Y., and Kuroda Y. Diagnosis and molecular analysis of three male patients with thiamine-responsive pyruvate dehydrogenase complex deficiency. J. Neurol. Sci. 201 (2002) 33-37
3. Lopez L.C., Schuelke M., Quinzii C.M., Kanki T., Rodenburg R.J., Naini A., Dimauro S., and Hirano M. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am. J. Hum. Genet. 79 (2006) 1125-1129
4. Quinzii C., Naini A., Salviati L., Trevisson E., Navas P., Dimauro S., and Hirano M. A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am. J. Hum. Genet. 78 (2006) 345-349
5. Tanaka M., Nishigaki Y., Fuku N., Ibi T., Sahashi K., and Koga Y. Therapeutic potential of pyruvate therapy for mitochondrial diseases. Mitochondrion 7 (2007) 399-401
6. Leigh D. Subacute necrotizing encephalomyelopathy in an infant. J. Neurol. Neurosurg. Psychiatry 14 (1951) 216-221
7. Finsterer J. Leigh and Leigh-like syndrome in children and adults. Pediatr. Neurol. 39 (2008) 223-235
8. Morris A.A., Leonard J.V., Brown G.K., Bidouki S.K., Bindoff L.A., Woodward C.E., Harding A.E., Lake B.D., Harding B.N., Farrell M.A., Bell J.E., Mirakhur M., and Turnbull D.M. Deficiency of respiratory chain complex I is a common cause of Leigh disease. Ann. Neurol. 40 (1996) 25-30
9. Rahman S., Blok R.B., Dahl H.H., Danks D.M., Kirby D.M., Chow C.W., Christodoulou J., and Thorburn D.R. Leigh syndrome: clinical features and biochemical and DNA abnormalities. Ann. Neurol. 39 (1996) 343-351
10. DiMauro S., Nicholson J.F., Hays A.P., Eastwood A.B., Papadimitriou A., Koenigsberger R., and DeVivo D.C. Benign infantile mitochondrial myopathy due to reversible cytochrome c oxidase deficiency. Ann. Neurol. 14 (1983) 226-234
11. Hermann H.P., Pieske B., Schwarzmuller E., Keul J., Just H., and Hasenfuss G. Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study. Lancet 353 (1999) 1321-1323
12. Weiss R.G., Gloth S.T., Kalil-Filho R., Chacko V.P., Stern M.D., and Gerstenblith G. Indexing tricarboxylic acid cycle flux in intact hearts by carbon-13 nuclear magnetic resonance. Circ. Res. 70 (1992) 392-408
13. Moriyama M., Li M.X., Kobayashi K., Sinasac D.S., Kannan Y., Iijima M., Horiuchi M., Tsui L.C., Tanaka M., Nakamura Y., and Saheki T. Pyruvate ameliorates the defect in ureogenesis from ammonia in citrin-deficient mice. J. Hepatol. 44 (2006) 930-938
14. Mutoh K., Kurokawa K., Kobayashi K., and Saheki T. Treatment of a citrin-deficient patient at the early stage of adult-onset type II citrullinaemia with arginine and sodium pyruvate. J. Inherit. Metab. Dis. (2008) electronic publication pubmed id: 18958581